For the past several weeks, we’ve been updating our 2008 Corporate Presentation. It’s finally complete and we’re excited to share it with you. Feel free to download a copy of the Presentation by clicking on the image above or by clicking here.

(Adobe Acrobat Reader is required to view this document. If you do not have Adobe Acrobat Reader, click here to download it.)

Dear Fellow Shareholders of Nutra Pharma:

As the Chairman, Chief Executive Officer, and fellow investor in the Company, I am excited and pleased to share with you the recent progress we have made in our drug research.

Last week marked one of the most exciting accomplishments for our company. As many of you read in our press release; on Tuesday, our wholly-owned drug discovery subsidiary, ReceptoPharm, successfully completed its 15-month Phase IIb/IIIa clinical trial for the treatment of Adrenomyeloneuropathy (AMN).

As our first Phase II trial to be completed, this not only adds tremendous credibility to our research, but it also provides additional evidence supporting the safety and efficacy of our leading drug candidate for neurological and autoimmune disorders, RPI-78M.

Although data from the Trial is still being collected and analyzed, initial feedback from physicians involved in the trial was positive. We look forward to presenting our data by the end of September.

As part of our ongoing commitment to maintain a high level of transparency and communication with our shareholders and those interested in our company, we continue to post articles to the NPC Blog. We invite you to read our recent entries, which include in-depth commentaries about our work with Adrenomyeloneuropathy and Nontuberculous Mycobacteria. You can also opt-in to receive these posts through your email by filling out and submitting the “Blog Updates” form when you visit the blog at the above address.

In addition to the NPC Blog, we post our recent press announcements online. If you would like to receive the latest news from the Company, I invite you to subscribe to our “E-Alerts”. Just visit http://www.NutraPharma.com, fill out the “E-Alerts” form on the lower left column of the homepage and click “subscribe”. “E-Alerts” are separate from “Blog Updates”, so you will need to sign up for each individually if you would like to receive both company news and blog posts by email.

As always, if you have any additional questions or would like more information, please contact the Investor Relations Hotline at (877) 895-5647.

Sincerely yours,
Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation